Our top pick for
Kamada Ltd is a drug manufacturers-specialty & generic business based in the US. Kamada shares (KMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Kamada employs 429 staff and has a trailing 12-month revenue of around USD$133.8 million.
|Latest market close||USD$7.19|
|52-week range||USD$4.4 - USD$13.33|
|50-day moving average||USD$6.6041|
|200-day moving average||USD$8.1668|
|Wall St. target price||USD$11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.48|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||8.77%|
|1 month (2020-12-15)||10.62%|
|3 months (2020-10-15)||-9.45%|
|6 months (2020-07-15)||-18.11%|
|1 year (2020-01-15)||11.30%|
|2 years (2019-01-15)||34.90%|
|3 years (2018-01-12)||27.26%|
|5 years (2016-01-15)||81.57%|
Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kamada's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Kamada shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$25.9 million.
The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$133.8 million|
|Operating margin TTM||16.5%|
|Gross profit TTM||USD$49.7 million|
|Return on assets TTM||7.6%|
|Return on equity TTM||13.6%|
|Market capitalisation||USD$290.9 million|
TTM: trailing 12 months
There are currently 572,349 Kamada shares held short by investors – that's known as Kamada's "short interest". This figure is 3.8% up from 551,400 last month.
There are a few different ways that this level of interest in shorting Kamada shares can be evaluated.
Kamada's "short interest ratio" (SIR) is the quantity of Kamada shares currently shorted divided by the average quantity of Kamada shares traded daily (recently around 131574.48275862). Kamada's SIR currently stands at 4.35. In other words for every 100,000 Kamada shares traded daily on the market, roughly 4350 shares are currently held short.
However Kamada's short interest can also be evaluated against the total number of Kamada shares, or, against the total number of tradable Kamada shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kamada's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Kamada shares in existence, roughly 10 shares are currently held short) or 0.0198% of the tradable shares (for every 100,000 tradable Kamada shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kamada.
Find out more about how you can short Kamada stock.
We're not expecting Kamada to pay a dividend over the next 12 months.
Over the last 12 months, Kamada's shares have ranged in value from as little as $4.4 up to $13.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.4198. This would suggest that Kamada's shares are less volatile than average (for this exchange).
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company's products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent that are in Phase II stage; and Inhaled AAT for AAT deficiency, which is in Phase II and III stages. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was founded in 1990 and is headquartered in Rehovot, Israel.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.